All Eyes Are on Clinical Trials - COVID-19 Clinical Trial
Breaking News | COVID-19

All Eyes Are on Clinical Trials

Actemra by Roche 

Roche’s arthritis drug Actemra is working with the FDA to start a randomized, double-blind, placebo-controlled phase 3 clinical trial to study Actemra in hospitalized patients with severe COVID-19 pneumonia caused by the novel coronavirus. Roche and its partner, U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, plan to officially begin enrolling patients in early April in different parts of the world, including the U.S. 


Ritonavir/Lopinavir 

This combination drug, sold under the brand name Kaletra, was approved in the US in 2000 to treat HIV infections. Abbott Laboratories developed lopinavir specifically to inhibit the protease of HIV, an important enzyme that cleaves a long protein chain into peptides during the assembly of new viruses. Because lopinavir is quickly broken down in the human body by our own proteases, it is given with low levels of ritonavir, another protease inhibitor, that lets lopinavir persist longer. 


Ritonavir/Lopinavir + Interferon Beta 

World Health Organizations SOLIDARITY study will have an arm that combines two antivirals drugs Ritonavir/lopinavir with interferon-beta, a molecule involved in regulating inflammation in the body that also has shown an effect in marmosets infected with MERS. A combination of the three drugs is now being tested in MERS patients in Saudi-Arabia in the first randomized controlled trial for that disease


Chloroquine and Hydroxychloroquine 

Hydroxychloroquine has already demonstrated the ability to kill or reduce the coronavirus in laboratory petri dishes, so the next step is to perform a patient trial. Researchers in Marseilles, France are currently performing the first patient trial of Plaquenil for COVID-19. The results have not yet been published, but the initial findings are available to the public. The drugs work by decreasing the acidity in endosomes, compartments inside cells that they use to ingest outside material and that some viruses can coopt to enter a cell. But the main entryway for SARS-Cov-2 is a different one, using its so-called spike protein to attach to a receptor on the surface of human cells. Studies in cell culture have suggested chloroquines have some activity against SARS-CoV-2, but the doses needed are usually high—and could cause serious toxicities.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.